

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12N 1/20, A61K 35/74, A61L 15/36 // (C12N 1/20, C12R 1:25)	A1	(11) International Publication Number: WO 99/45099 (43) International Publication Date: 10 September 1999 (10.09.99)
(21) International Application Number: PCT/SE99/00336 (22) International Filing Date: 5 March 1999 (05.03.99) (30) Priority Data: 9800749-5 6 March 1998 (06.03.98) SE 9801951-6 2 June 1998 (02.06.98) SE (71) Applicant (for all designated States except US): SCA HYGIENE PRODUCTS AB [SE/SE]; S-405 03 Göteborg (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): HÅKANSSON, Eva, Grahns [SE/SE]; Nygatan 74, S-903 31 Umeå (SE). FORSGREN-BRUSK, Ulla [SE/SE]; Plommonvägen 35, S-435 43 Pixbo (SE). ANDERSSON, Rolf [SE/SE]; Vallmovägen 11, S-435 31 Mölnlycke (SE). HOLM, Stig, E. [SE/SE]; Norra Gimonäsvägen 25, S-907 38 Umeå (SE). HÅKANSSON, Stellan [SE/SE]; Nygatan 74, S-903 31 Umeå (SE). (74) Agents: BERG, S., A. et al.; Albihns Patentbyrå Stockholm AB, P.O. Box 5581, S-114 85 Stockholm (SE).		(81) Designated States: AU, BR, CN, CZ, JP, KR, MX, NZ, PL, RU, SK, TR, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: NEW AGENT (57) Abstract A novel strain of <i>Lactobacillus plantarum</i> , referred to as LB931, has now been isolated. The strain has been deposited at Deutsche Sammlung von Mikroorganismen, Braunschweig, DE. It has been assigned accession number DSM11918. Accordingly LB931 can be used for treating and/or preventing urogenital infections. LB931 can advantageously be included in pharmaceutical compositions and in products for personal care, such as feminine hygiene products, diapers and sanitary napkins.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

New agent

The present invention relates to a novel *Lactobacillus* strain, which possesses valuable pharmaceutical characteristics. The invention also relates to pharmaceutical compositions and products for personal care comprising the strain, as well as use of the strain for prevention of urogenital infections.

Technical background (All citations in the following description are incorporated by reference).

10

The usual bacterial flora in the urogenital region is constituted by a complex ecosystem comprising more than 50 different bacterial species (Hill et al., Scand. J. Urol. Nephrol. 1984;86 (suppl.):23-29). The normal flora is dominated by bacteria belonging to the genus *Lactobacillus* (LB) which are Gram positive rods adapted to the environment in the vagina of the fertile woman. These bacteria also contribute to the maintenance of the specific milieu and the ecological balance in the vagina.

15

Beside the complex interaction pattern of the multitudinous bacterial flora of the vagina and the rest of the urogenital region, it is necessary to consider the variation of physical conditions that can influence bacterial growth and adhesion properties. Some LVS strains inhibit growth of potentially pathogenic bacteria by various mechanisms. The metabolism of LB results in formation of organic acids, above all lactic acid and acetic acid, which contribute to the low pH of vaginal fluid which is unfavourable for many other species. LB may also produce soluble substances which directly inhibit growth of potentially pathogenic bacteria and yeast. They can also produce hydrogen peroxide which is toxic to bacteria lacking the enzyme catalase, such as gram-negative anaerobic rods and *Enterobacteriaceae*. These inhibiting characteristics may vary considerably between different LB strains (Hooton et al., JAMA 1990; 265:64-69).

20

25

30

Weakness of the natural defence system may allow potentially pathogenic micro-organisms to cause clinical infection, for example in connection with medication, inferior personal care, or shifts in the microflora of skin or mucous membranes. The normal flora of the vagina is dominated by LB and the surrounding pH is lower than 4.5. Yeast and enterobacteria are scanty or absent (Redondo-Lopez et al., Rev. Inf. Dis. 1987; 12:856-872). Shifts of the vaginal bacterial flora can be found in connection with different pathogenic conditions. There is an increased amount of enterobacteria in the vagina and urethral orifice of women suffering from recrudescant urinary tract infections and they also have a urogenital flora depleted of lactobacilli (Marrie et al. J. Clin. Microbiol. 1976, 8, 67-72). It is also known that the frequency of infections increase in connection with antibiotic treatment of other infections (Stamey, Rev. Inf. Dis. 1987; 9(suppl. 2):195-208; Reid et al., Curr. Opin. Inf. Dis. 1991; 4:37-41). In addition, it has been demonstrated that children who have a history of frequent episodes of antibiotic treatment are more prone to contract urinary tract infections (Mårild et al., Ped. Inf. Dis. 1990; 22:43-47).

In bacterial vaginosis the amount of LB is decreased and pH is increased. There is also a dominance of *Bacterioides* species, *Gardnerella vaginalis* and *Mobiluncus* (Redondo-Lopez, *supra*). Vaginitis, associated with an increased amount of enterobacteria, is often a tangible problem in connection with antibiotic treatment. Common oral administration of penicillin results in the accumulation of the substance in vaginal fluid (Sjöberg et al., Obstet. Gynecol. 1990; 75:18-21) followed by colonisation by enterobacteria and yeast (Sjöberg et al., Gynecol. Obstet. Invest. 1992; 33:42-46). Investigations in monkeys (*Macaca fascicularis*) have revealed that vaginal administration of amoxicillin impairs the ability of the normal bacterial flora to inhibit colonisation of urinary tract-pathogenic *E. coli* (Herthelius et al., Infection 1988; 16:263-266).

During pregnancy the composition of the vaginal flora may influence the morbidity of the fetus and child. Occurrence of group B streptococci (GBS) in the faecal and vaginal flora is common (up to 30% of all pregnant women). These bacteria do not

normally constitute a threat to the woman's health. However, GBS may cause serious infections in the new-born child. In these cases, bacteria are transmitted vertically from mother to child before or in connection with birth. Other bacteria can also be transmitted in this way and cause infections in the child. There is also a strong connection between bacterial vaginosis and premature birth (Martius et al., Arch. Gynecol. Obstet. 1990; 247:1-13). The mechanisms behind this phenomenon are not known. It has been shown that a shift of the vaginal flora towards dominance of Gram negative species increases the amount of the enzyme phospholipase A2, which in turn may initiate prostaglandin synthesis starting from arachidonic acid (Bejar et al., Obstet. Gynecol. 1981; 57:479-482). The vaginosis flora also produces large amounts of endotoxin (Sjöberg et al., Obstet. Gynecol. 1991; 77:265-266), which may induce endogenous prostaglandin synthesis (Romero et al., Obstet. Gynecol. 1989; 73:31-34), possibly mediated by interleukines.

15. The theoretically positive characteristics of LB have motivated their use in commercial preparations with the intend use to supplement and strengthen the vaginal flora. Success has been variable and often the available preparations contain considerably lower numbers of LB than what has been stated. Some preparations have also been contaminated (Hughes et al., Obstet. Gynecol., 1990; 75(2):244-248). In order to supplement and improve the normal bacterial flora in the urogenital region by addition of LB, it is necessary to carefully select the bacterial strains to be used. A LB strain that is suitable for this purpose should fulfil the following criteria:

1. The LB strain should produce high amounts of soluble substances with growth inhibiting capacity on enterobacteria, group B streptococci, staphylococci and yeast.
2. The LB strain should be able to be transferred to skin and mucosal surfaces of the urogenital region.
3. The LB strain should be able to adhere to epithelial surfaces in the urogenital region.

4. The LB strain should be able to endure storage for a long period of time, and it must be possible to induce the strain in different kinds of preparations.
 5. The LB strain should be able to retain its viability and characteristics in an article or preparation upon use.
 - 5 6. The LB strain should not be sensitive to spermicidal preparations containing nonoxynol-9.
 7. The LB strain should be isolated from the urogenital tract of human female.
 8. The LB strain should permit existence of the human urogenital LB flora.
- 10 Therefore, there is a demand for strains, fulfilling these requirements.

Summary of the invention

A novel strain of *Lactobacillus plantarum*, referred to as LB931, has been isolated,
15 which fulfils requirements listed above. The strain has been deposited at Deutsche Sammlung von Mikroorganismen, Braunschweig, DE. It has been assigned accession number DSM11918. Accordingly LB931 may be used for treating and/or preventing urogenital infections. LB931 can advantageously be included in pharmaceutical compositions and in products for personal care, such as diapers and sanitary
20 napkins.

Definitions

As disclosed herein, the term "LB" refers to bacteria of the genus *Lactobacillus*.

25

As disclosed herein, the term "Urogenital region" refers to perineum, urethra and vagina.

As disclosed herein the term "absorbent article" relates to products suitable for absorbing a body fluid, such as blood or urine. Examples of such articles are feminine
30 hygiene products, incontinence guards, and diapers.

As disclosed herein, the term "GBS" refers to group B *Streptococcus*.

As disclosed herein, the term "lactic acid bacteria" relates to bacteria producing
5 lactic acid, such as bacteria belonging to the genera *Lactobacillus* and *Lactococcus*.

By the term "cfu" is meant colony-forming units.

Detailed description of the invention

10

The present invention relates to a novel strain of *Lactobacillus plantarum*, referred to as LB931 (DSM11918). This bacterial strain is valuable for preventing and/or treating urogenital infections as it inhibits growth of a large number of pathogenic micro-organisms. The strain is durable and readily survives long periods of storage in room temperature. Accordingly products containing LB931 have a long shelf
15 life. The strain can easily be transferred to the human skin and vaginal epithelium. LB931 is resistant to therapeutic concentrations of some antibiotic substances and spermacidal compounds.

20 The inhibition characteristics of LB931 has been investigated. Examples of bacteria species which are successfully inhibited are *Escherichia*, *Klebsiella*, *Proteus*, *Staphylococcus* and group B *Streptococcus*. LB931 is therefore useful for preventing and/or treating infections caused by these micro-organisms.

25 As noted above, the present invention also provides a variety of pharmaceutical compositions, preferably suitable for topical administration, comprising LB931 along with pharmaceutically or physiologically acceptable carriers, excipients and/or diluents. Generally, such carriers should be non-toxic to recipients at the dosages and concentrations employed. Normally, the preparation of such compositions
30 entails the combination of the therapeutic agent with buffers, thickening agents of gel-forming agents such as glycerine, polyethylene glycol, etc. Antioxidants such

as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, carbohydrates including glucose, sucrose and dextrans, and other stabilisers and excipients may be included. Possible pharmaceutical compositions are ointments, creams, liquid solutions, suppositories or capsules.

5

The present invention also relates to absorbent articles comprising LB931. Such an article may include a permeable outer sheet which is intended to be in close contact with the skin of the wearer, a preferably liquid-impermeable backing sheet which is intended to lie distal from the wearer in use, and an absorbent structure arranged between the outer sheet and the backing sheet. In some cases, an additional sheet in the form of e.g. wadding or like material, may be placed between the outer sheet and the absorbent structure. The micro-organisms exhibiting antagonistic properties may be arranged in different parts of the absorbent article, for instance in the outer sheet, in the absorbent structure of the absorbent article, between two of the layers of the absorbent article, in a loose insert product in the absorbent article, or in some other way.

10

15

20

The present invention will now be described with reference to the enclosed figures in which:

Fig. 1 is a diagram showing the stability of freeze-dried LB931 at room temperature (+22°C) and at +6°C;

25

Fig. 2 is a diagram showing the stability of LB931 impregnated on an absorbent article;

Fig. 3 and 4 disclose the amount of LB931 transferred to the urethral orifice and perineal skin in young girls after using a panty liner comprising LB931.

The present invention will now be described with reference to the following examples:

Example 1: Isolation and typing of *Lactobacillus plantarum*, strain LB931

5

Bacterial samples were taken from healthy women. From these samples, bacterial strains were isolated and these strains were screened on the basis of their ability to inhibit growth of enterobacteria (data not shown). The best strain, isolated from a healthy pregnant woman, was classified as *Lactobacillus plantarum* according to the test kit API 50 CH (API systems, BioMerieux, FR), and was denominated LB931. The strain was further typed by DNA-analysis with SDS-page at BCCM/LMG (Belgium) to be *Lactobacillus plantarum-pentosus-paraplanarum*.

10

Example 2: Inhibition capacity of strain LB931

15

The purpose of this experiment was to illustrate the ability of strain LB931 to inhibit growth of other bacteria. LB931 was grown in MRS broth (Merck, DE) at a temperature of 37°C in 5% CO₂ over night. One ml, containing 10⁸ bacteria was added to 25 ml of melted 2% agar in MRS-broth. The mixture was poured into the Petri dish, allowed to congeal and incubated as described above for 24 hours. Another 25 ml of M17-agar (Merck, DE) was poured on top of the first layer and the plates were left at room temperature for 4 hours. Similar agar plates without LB931 were also made and used as control plates.

20

The indicator bacteria were cultured separately in TY-medium (Holm et al., APMIS 1967; 69, 264) at 37°C in air. The cultures were transferred to a 25 compartment Bertani tray, each compartment holding 0,25 ml (10⁶ bacteria/ml). From each of these trays the bacteria were transferred and stamped onto the agar plates containing the *Lactobacillus*, using the Steer's steel pin replicator (Steers et al. J. Antibiot. Chemother. 1979, 9, 307). The plates were incubated in 37°C overnight. The plates

25

30

were read and it was established whether a) the indicator bacteria had grown; b) the growth of the indicator bacteria had been inhibited; or c) no growth of the indicator bacteria had occurred. The pH of each of the plates were also monitored.

- 5 The results of the interference tests are shown in table 1.

Table 1

Indicator bacterial sp.	Inhibition	
	%	No/total
Coagulase negative staphylococci	90	9/10
Group B streptococcus sp.	100	19/19
Lactobacillus sp.	7	1/14
Klebsiella sp.	100	50/50
E. coli	100	50/50
Proteus sp.	100	50/50

- 10 The results show that *Lactobacillus plantarum*, LB931 inhibits or prevents growth of a large number of bacterial strains, and that other *Lactobacillus* strains are mostly unaffected.

Example 3: The survival capabilities of LB931 in different preparations

15

- a) LB931 dissolved in a suspension of equal parts skim milk and 0.9% NaCl

LB931 was dissolved in skim milk containing 0.9% NaCl. The dissolved bacteria was then incubated at different temperatures. The amount of bacteria was continu-

20 ously monitored by cell counting. The results are disclosed in table II below.

Table II

	No. of bacteria (CFU)			
Temperature (°C)	Day 0	Day 2	Day 5	Day 32
4	7.8×10^{10}			2.2×10^{10}
20	1.8×10^{10}		2.2×10^{10}	
27	1.8×10^{10}	1.2×10^{10}	3.3×10^9	
37	1.8×10^{10}	5.8×10^9	1.0×10^5	

The results show that LB931 is stable in a mixture of skim milk and NaCl for a period of one month at +4°C.

b) A skim milk preparation of LB931 was freeze-dried according to standard methods. The obtained powder was stored in Petri dishes at room temperature and at +6°C. The number of bacteria was determined after 7 days and 25 days, respectively. The results are disclosed in table III below.

Table III

	No. of bacteria (CFU)		
Temperature (°C)	Day 0	Day 7	Day 25
6	4.2×10^8	2.2×10^8	1.2×10^8
22	4.2×10^8	1.9×10^8	1.4×10^8

The number of bacteria in the freeze-dried powder was also monitored every fourth week up to 68 weeks. These results are presented in fig. 1. It is evident from the figure that LB931 is stable both at room temperature and +6°C for 22 weeks. After one year, at +6°C, more than 10^5 cfu/mg LB931 is viable.

- c) The ability of LB931 to survive in synthetic urine, pH 6,6, was tested. The synthetic urine contains mono-, a divalent cat- and anions as well as urea and was prepared acc to specifications in Geigy, Scientific Tables, vol. 2, 8:th ed. 1981 p 53. To the sterile synthetic urine, nutrient medium for microorganisms was added. The nutrient medium was prepared according to data from the composition of Hook- and FSA-media. To 1 ml of synthetic urine 10^3 LB931 bacteria were added, and the samples were incubated for 18 h at 32°C. After incubation the number of bacteria in the sample was $> 10^5$ /ml. LB931 is able to survive and grow in synthetic urine.
- 10 d) The ability of LB931 to survive on an absorbent article (panty liner) was investigated. A suspension of LB931 (150 μ l) was added to the absorbent article, and this article was subsequently stored in a tight package up to 9 months. The results are shown in fig. 2. A great number of bacteria survived for seven months.
- 15 e) Finally the LB931 was tested about its characteristics over a period of growth and storage. LB931 was cultivated in MRS-broth and a new passage was made every third day for three months. After that the start sample of LB931 and the last passage was compared in the API-test, PGFE and interference test. The two samples were identical in all the tests. This shows that LB931 is very stable after storage and several passage in growth medium.
- 20

Example 4: Transfer of LB931 to perineum skin and urethral orifice in woman

In order to study transfer of LB931 to perineum when using a pantry liner, the following investigation was carried out. All test persons were women between 12 and 60 years of age, and the tests were carried out between menstrual periods when appropriate. Test products were manufactured from conventional panty liners comprising a liquid-permeable outer layer, a liquid-impermeable rear-side layer and between an absorbent layer of 100-200 g/m² of chemical cellulose pulp. On the absorbing side of the test product a suspension of LB931 bacteria was sprayed in an amount of 10^9 colony-forming units a product.

25

30

In order to determine the presence of LB931 in perineum of the 13 test persons, a so called swab test was carried out. Bacteria were collected by rubbing a sterile stick comprising a cotton tip which has been immersed into sterile sodium chloride solution on to a defined skin area. The occurrence of LB931 and other LB on perineal skin and at the urethral orifice were determined. The test persons were determined in this manner in order to establish a blank sample. Then, the test persons wore the panty liner during 5 hours in the morning. The panty liner was removed and the occurrence of added lactic acid bacteria and natural lactic acid bacteria, respectively, was determined again, directly after removing the panty liner. This sample was referred to as sample 1. After 4 - 5 more hours a further sample was taken, and was referred to as sample 2. The lactic acid bacteria type was identified using Rogosa-agar with vancomycin for LB931 and Rogosa-agar plates incubated anaerobic for other LB. Further identification was done by API (BioMerieux, FR) and PFGE (pulsed field electrophoresis). The results are shown in table IV. LB931 could be found on perineum skin or urethral orifice in all women after using panty-liner sprayed with LB931.

Person No.	TABLE IV	Sample 1		Sample 2	
		Urethral orifice	Perineal skin	Urethral orifice	Perineal skin
1	Lb931	2×10^2	4×10^4	0	0
	Endogenous LB flora	0	0	0	0
2	Lb931	6×10^1	7×10^3	0	2×10^2
	Endogenous LB flora	0	0	0	0
3	Lb931	1×10^3	1×10^2	1×10^1	5×10^1
	Endogenous LB flora	0	0	0	0
4	Lb931	1×10^2	3×10^2	3×10^1	1×10^3
	Endogenous LB flora	+	+	+	+
5	Lb931	2×10^1	3×10^3	2×10^1	1×10^1
	Endogenous LB flora	+	0	+	+
6	Lb931	1×10^2	2×10^2	1×10^1	7×10^1
	Endogenous LB flora	+	+	+	+
7	Lb931	2×10^3	8×10^3	1×10^2	7×10^1
	Endogenous LB flora	+	+	+	+
8	Lb931	2×10^1	4×10^3	0	8×10^1
	Endogenous LB flora	0	0	0	0
9	Lb931	9×10^1	2×10^2	0	8×10^1
	Endogenous LB flora	+	+	+	+
10	Lb931	3×10^3	2×10^3	7×10^2	4×10^3
	Endogenous LB flora	0	0	0	0
11	Lb931	2×10^2	6×10^2	3×10^2	2×10^2
	Endogenous LB flora	+	+	+	+
12	Lb931	7×10^1	9×10^2	0	1×10^1
	Endogenous LB flora	0	0	0	0
13	Lb931	5×10^2	7×10^2	7×10^2	7×10^1
	Endogenous LB flora	0	0	0	0
No Lb931 positive:		13	13	8	12

Example 5: Transfer of LB931 to perineum skin and urethral orifice in girls

Thirteen young girls between 3 and 12 years old were included in study. Bacterial samples from the perineal skin and urethral orifice were obtained by first immersing a cotton swab in MRS-broth, then gently rubbing the stick on the skin or epithelial surface. Finally the swab was immersed in a sample tube containing MRS-broth.

Samples were obtained according to the following scheme:

Sample 0: A blank sample was obtained in the evening before entering the study comprising LB931 bacteria. Evening, day 1; a panty liner was put on.

Sample 1: Morning, day 2. A new panty liner is worn during the day;

Sample 2: A sample was taken in the evening before an optional bath and before putting on a new panty liner. Evening, day 2;

Sample 3: Same procedure as for sample 1. Morning, day 3;

Sample 4: Same procedure as for sample 2. Evening, day 3;

Sample 5: Same procedure as for sample 1. Morning, day 4;

Sample 6: A sample is taken in the evening before an optional bath. No panty liner is worn during the night. Evening, day 4;

Sample 7: A sample is taken in the morning day 5. No panty liner is worn during the day.

Sample 8: The last sample is taken in the evening day 5.

The results are presented in fig. 3 (urethral orifice) and fig. 4 (Perineum skin). The results show that LB931 can be transferred from an absorbent article.

10

Example 6: Sensitivity to antibiotics and spermicidal agents

MIC values of *Lactobacillus plantarum* LB931 were determined using E-test (Brown et al. J Antimicrob Chemother 1991;27:185-190). The results are disclosed in table V below.

15

Table V

Antibiotic substance	MIC µg/ml
Ampicillin	0.19
Cefotaxime	0.094
Cefuroxime	0.38
Gentamycin	0.25
Imipenem	0.016
Metronidazole	>32
Erythromycin	0.25
Vancomycin	>256
Piperacin/Tazobactam	2
Tetracyclin	2
Trimetoprim	0.016
Benzylpenicillin	0.5

The sensitivity to antibiotic substances was also determined using the SIR system. In table VI below S means sensitive and R stands for resistant.

Table VI

Antibiotic substance	Zone (mm)	Indication
Cefadroxil	24	S
Clindamycin	35	S
Tri/sulfamethoazole	43	S
Ceftazidime	35	S
Amikacin	30	S
Aztreonam	0	R
Mecillinam	0	R
Nalidixin acid	0	R
Netilmycin	0	R
Nitrofuantin	36	S
Norfloxacin	0	R
Tobramycin	32	S
Mecillinam/Ampicillin	41	S
Cefiprome	47	S
Oxacillin	0	R
Cefalotin	22	S

LB931 is sensitive to some antibiotics usually prescribed for urinary tract infections but LB931 is also resistant to for example Nalidixin acid and Norfloxacin. LB931 is
 5 also resistant to Vancomycin.

MIC tests were also carried out for the spermicidal agent Tergitol. LB931 was grown on MRS agar in 5% CO₂, 37 °C for 48 h. The bacteria were inoculated in 3 ml MRS broth and incubated for 10 h under the same conditions as previously.
 10 1.5 % of the culture was reinoculated to 3 ml MRS broth and was incubated under the same conditions for 18 h. NP-9 Tergitol (Sigma, US) Lot 47F0002 was diluted in MRS broth having a temperature of 37 °C (reduced viscosity) to a stock solution

of 40 %. Using this stock solution, 3 ml solutions of the following concentrations were prepared: 0 %, 5 %, 10 %, 20 %, 30 %, and 40 %. 10 µl bacterial culture was added to each solution. The blank solution was mixed and added to MRS agar plates. The plates were grown in 5 % CO₂, 37 °C for 48 h for determining the cell density. The rest of the solutions were incubated without mixing in 5 % CO₂, 37 °C for 18 h. The solution containing 30 % and 40 % NP-9 were diluted in 37 °C MRS broth (reduced viscosity). All solutions were vigorously mixed, diluted in sterile 0.9 % NaCl and added to MRS agar plates. The plates were incubated in 5 % CO₂, 37 °C for 48 h for determining cfu/ml.

10

The results are disclosed in table VII below.

Inoculated amount of LB931 was 1.0×10^7 cfu

Tergitol NP-9	Cfu/ml LB931
0 %	2.6×10^9
1 %	2.5×10^9
5 %	2.5×10^9
10 %	1.6×10^9
20 %	1.4×10^9
30 %	1.0×10^9
40 %	6.9×10^7

15 The results show that LB931 is able to survive well in up to 40 % tergitol NP-9.

Example 7: Adherence of LB931 to vaginal epithelial cells

a) Preparation of a suspension of LB931

LB931 was grown on MRS agar (5 % CO₂, 37 °C; 48 h). The culture was inoculated to 3 ml broth (5 % CO₂; 37 °C; 8 h). 2 % of the resulting culture was reinoculated to 10 ml MRS broth (5 % CO₂; 37 °C; 18 h). The resulting culture was centrifuged for 8 min at 20 °C and at 2000 rpm in a swing-out rotor (820 x g). The obtained

20

cell pellet was washed in 5 ml lactic acid buffer (10 mM lactic acid, pH 4.5, 0.15 M NaCl). The bacteria are diluted in lactic acid buffer until OD₅₀₀ is about 1.0 (about 10⁸ cfu/ml)

5 b) Preparation of vaginal epithelial cells:

Vaginal epithelial cells were harvested using a sterile cotton stick, and the cells were transferred to 4 ml lactic acid buffer or PBS in a small tube. The tube was mixed and the cotton stick was removed. The tube was centrifuged at 700 rpm at 20 °C for 8 min. in a Jouan CR.-12 swingout - rotor ($\approx 100 \times g$), and the obtained pellet was
10 washed in 3 ml lactic acid buffer or PBS. The cells were counted in a hematocytometer and the concentration was adjusted to 10⁵-10⁶ cells/ml by using lactic acid buffer or PBS. 25 μ l cells were spread on a microscope slide for controlling the washing procedure (see below):

15 c) Adherence tests

0.5 ml LB931 suspension and 0.5 ml cell suspension were briefly mixed in a 1.5 ml eppendorf tube. A control sample was prepared by mixing 0.5 ml cell suspension and 0.5 ml buffer. The tubes were centrifuged at 20 °C and 2000 rpm ($\approx 720 \times g$), and subsequently incubated for 1 h at 37 °C. After the incubation, the tubes were
20 centrifuged for 8 min. at 20 °C at 700 rpm ($\approx 90 \times g$). The pellets were washed in 1 ml lactic acid buffer or PBS. Finally, the pellet was suspended in 400-500 μ l lactic acid buffer or PBS.

d) Analysis

25 25 μ l of a suspended pellet was allowed to air-dry on a microscope slide, followed by fixation and Gram-staining. From each sample 50 epithelia cells are analysed. The number of LB931 adhered to the cells are counted and the results are divided in five groups (0-10, 11-30, 31-50, 51-100, >100 bacteria/cell).

30 The results are disclosed in Table VIII below:

Table VIII

Number of test persons: 5

Sampling occasions: Before menstruation (bm); Ovulation (Ov)

Epithelia cells samples	Adhered LB931/epithelia cell				
	0-10	11-30	31-50	51-100	>100
(bm) incubated with LB931, pH 4.5	17.2*	24.8	14.4	15.6	28.0
(bm) incubated control cells, pH 4.5	99.6	0.4			
(Ov) incubated with LB931, pH 4.5	8.4	22.8	19.2	20.0	29.6
(Ov) incubated control cells, pH 4.5	98.4	1.6			

5 * figures are given in percent.

The results clearly shows that LB931 bacteria adhere well to vaginal epithelial cells independent when the cells are sampled.

Claims

1. *Lactobacillus plantarum*, strain LB931, which has been deposited at Deutsche Sammlung von Mikroorganismen, and been assigned accession number DSM11918.
- 5 2. *Lactobacillus plantarum*, strain LB931, which has been deposited at Deutsche Sammlung von Mikroorganismen and been assigned accession number DSM11918, for medical use.
- 10 3. A pharmaceutical composition comprising *Lactobacillus plantarum*, strain LB931, which has been deposited at Deutsche Sammlung von Mikroorganismen, and been assigned accession number DSM11918, together with a pharmaceutically acceptable carrier and/or diluent.
- 15 4. A pharmaceutical composition according to claim 3, characterised in that it also comprises other lactic acid bacteria.
5. A pharmaceutical composition according to claim 3 comprising 10^4 to 10^{11} cfu, preferably 10^5 to 10^9 cfu, LB931.
- 20 6. A pharmaceutical composition according to claim 3 which is a suspension, spray, gel, cream, powder, capsule or a vaginal insert.
7. An absorbent product, such as a feminine hygiene product, diaper, sanitary napkin, panty guard or an incontinence guard, characterised in that it comprises *Lactobacillus plantarum*, strain LB931, which has been deposited at Deutsche Sammlung von Mikroorganismen, and been assigned accession number DSM11918.
- 25 8. An absorbent product according to claim 7 comprising 10^4 to 10^{11} cfu, preferably 10^5 to 10^9 cfu, LB931.
- 30

9. A pharmaceutical composition according to claim 5 wherein said pharmaceutical acceptable carrier is skimmilk or a lactobacillus growth factor in powder or other form.

5

10. Use of *Lactobacillus plantarum*, strain LB931, which has been deposited at Deutsche Sammlung von Mikroorganismen, and been assigned accession number DSM11918, for preparing a pharmaceutical composition for preventing and/or treating urogenital infections, such as colonisation of enterobacteria.

10


11. Use of *Lactobacillus plantarum*, strain LB931, which has been deposited at Deutsche Sammlung von Mikroorganismen, and been assigned accession number DSM11918, for producing an absorbent article, such as a diaper, sanitary napkin, panty guard or an incontinence guard, suitable for preventing and/or treating urogenital infections, such as colonisation of enterobacteria.


15

1/4

Fig. 1

Stability test, LB 931 (lyophilised)





2/4

Fig. 2

Stability of Lb 931 impregnated on an absorbent article,
"Soft Normal"




Fig. 3

Mean value of LB 931 during period day/night (urethra)






Fig. 4
Mean value of LB 931 during period day/night (perineum)





INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/00336

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C12N 1/20, A61K 35/74, A61L 15/36 // (C12N 1/20, C12R 1:25)
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, CA, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5705160 A (ANDREW W. BRUCE ET AL), 6 January 1998 (06.01.98), See table 3, column 9	1-11
X	WO 9729762 A1 (THE PROCTER & GAMBLE COMPANY), 21 August 1997 (21.08.97), See claim 6	1-11
X	WO 8404675 A1 (CHR. HANSEN'S BIO SYSTEMS A/S), 6 December 1984 (06.12.84), See claim 21	1-11
X	WO 9309793 A1 (REID, GREGOR), 27 May 1993 (27.05.93), See page 6, line 29	1-11

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

28 May 1999

Date of mailing of the international search report

20 -06- 1999

Name and mailing address of the ISA:

Swedish Patent Office
 Box 5055, S-102 42 STOCKHOLM
 Facsimile No. +46 8 666 02 86

Authorized officer

Yvonne Siösteen
 Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 99/00336

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0353581 A2 (DR. A. TOSI FARMACEUTICI S.R.L.), 7 February 1990 (07.02.90) --	1-11
A	FR 2656798 A1 (TARTUSKY GOSUDARSTVENNY UNIVERSITET ET AL), 12 July 1991 (12.07.91) -- -----	1-11

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/SE 99/00336

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
US	5705160	A	06/01/98	US 5804179 A	08/09/98
				CA 1298556 A	07/04/92
WO	9729762	A1	21/08/97	AU 1758197 A	02/09/97
				CA 2245810 A	21/08/97
				EP 0880354 A	02/12/98
WO	8404675	A1	06/12/84	AU 3018684 A	18/12/84
				DK 35685 A	25/01/85
				DK 242083 D	00/00/00
				EP 0147428 A	10/07/85
				JP 60501160 T	25/07/85
WO	9309793	A1	27/05/93	AU 2920592 A	15/06/93
				CA 2123709 A	27/05/93
				EP 0613374 A	07/09/94
				GB 2261372 A	19/05/93
				US 5645830 A	08/07/97
EP	0353581	A2	07/02/90	AT 113650 T	15/11/94
				DE 68919146 D	00/00/00
				IT 215183 Z	11/09/90
				JP 2174675 A	06/07/90
				US 5176911 A	05/01/93
FR	2656798	A1	12/07/91	WO 9105850 A	02/05/91

